Lopinavir/Ritonavir

Generic Name: Lopinavir/Ritonavir

Clinical Trials

Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r

Phase 4

Completed

Conditions: HIV/HCV Co-infection
HIV Infections

Interventions: Drug: Lopinavir/ritonavir with two nucleoside analogs
Drug: Lopinavir/ritonavir

First Posted Date: 2009-03-20

Last Posted Date: 2025-03-17

Lead Sponsor: Fundacion SEIMC-GESIDA

Target Recruit Count: 68

Registration Number: NCT00866021

Locations: 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸
Hospital General de Castellón, Castellón De La Plana, Castellón, Spain
🇪🇸
Hospital Donostia, San Sebastian, Guipuzcoa, Spain

and more 7 locations

Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: Eltrombopag and Lopinavir/Ritonavir
Drug: Lopinavir/Ritonavir
Drug: Eltrombopag

First Posted Date: 2009-02-02

Last Posted Date: 2017-11-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT00833378

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects

Phase 1

Terminated

Conditions: HIV
Tuberculosis

Interventions: Drug: lopinavir/ritonavir
Drug: rifabutin

First Posted Date: 2008-08-28

Last Posted Date: 2010-11-02

Lead Sponsor: Abbott

Target Recruit Count: 15

Registration Number: NCT00743470

Locations: 🇺🇸
Site Reference ID/Investigator# 11441, Waukegan, Illinois, United States

Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

Not Applicable

Completed

Conditions: Endothelial Dysfunction

Interventions: Drug: Atazanavir
Drug: Lopinavir/ritonavir
Drug: Placebo

First Posted Date: 2008-07-23

Last Posted Date: 2017-10-25

Lead Sponsor: Indiana University

Target Recruit Count: 30

Registration Number: NCT00720590

Locations: 🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States

Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART

Early Phase 1

Completed

Conditions: Malaria
HIV Infections

Interventions: Drug: Lamivudine
Drug: Lopinavir/Ritonavir
Drug: Nevirapine
Drug: Zidovudine

First Posted Date: 2008-07-21

Last Posted Date: 2016-09-19

Lead Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Target Recruit Count: 105

Registration Number: NCT00719602

Locations: 🇿🇲
George Clinic CRS (30273), Lusaka, Zambia
🇺🇬
Makerere University - JHU Research Collaboration (30293), Kampala, Uganda
🇲🇼
University of North Carolina Lilongwe (12001), Lilongwe, Malawi

Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations

Phase 1

Completed

Conditions: HIV Infections
Malaria

Interventions: Drug: efavirenz
Drug: lopinavir/ritonavir
Drug: artemether/lumefantrine

First Posted Date: 2008-06-16

Last Posted Date: 2013-06-06

Lead Sponsor: Fran Aweeka

Target Recruit Count: 38

Registration Number: NCT00697892

Locations: 🇺🇸
San Francisco General Hospital, San Francisco, California, United States

Pharmacokinetic Study of Two Generic Co-formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF)

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Lopinavir/ritonavir

First Posted Date: 2008-04-24

Last Posted Date: 2020-11-12

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 12

Registration Number: NCT00665951

Locations: 🇳🇱
Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands

Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV Patients

Phase 4

Terminated

Conditions: HIV Infections

Interventions: Drug: Nevirapine
Drug: Lopinavir/ritonavir

First Posted Date: 2008-04-18

Last Posted Date: 2019-12-05

Lead Sponsor: Germans Trias i Pujol Hospital

Target Recruit Count: 9

Registration Number: NCT00661349

Locations: 🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
🇪🇸
Hospital Clínico de Salamanca, Salamanca, Spain
🇪🇸
Hospital Universitario Príncipe de Asturias, Madrid, Spain

and more 6 locations

Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients

Phase 4

Completed

Conditions: Human Immunodeficiency Virus

Interventions: Drug: lopinavir/ritonavir

First Posted Date: 2008-04-01

Last Posted Date: 2013-03-15

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 207

Registration Number: NCT00648999

Locations: 🇲🇽
Site Ref # / Investigator 4049, Mexico City, Distrito Federal, Mexico
🇲🇽
Site Ref # / Investigator 4052, Oaxaca, Mexico
🇲🇽
Site Ref # / Investigator 4055, Culiacan, Sinaloa, Mexico

and more 10 locations

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

Phase 4

Terminated

Conditions: HIV Infections

Interventions: Drug: Lopinavir/Ritonavir
Drug: Raltegravir
Drug: Truvada

First Posted Date: 2008-03-11

Last Posted Date: 2018-08-29

Lead Sponsor: George Washington University

Target Recruit Count: 6

Registration Number: NCT00632970

Locations: 🇺🇸
George Washington University Medical Faculty Associates, Washington, District of Columbia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy